# Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

Source: https://onco.cc/trials/nct06105021/  
OnCo record `nct06105021` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AFNT-211 in pancreatic ductal adenocarcinoma, non-small-cell lung cancer and colorectal cancer, run by Affini-T Therapeutics, Inc., active and no longer recruiting.

## Summary

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor is a phase 1/2 interventional study registered as NCT06105021 by Affini-T Therapeutics, Inc., with 100 participants enrolled, started 2024-03-06 and due to reach its primary completion in 2025-12. Interventions recorded: AFNT-211.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06105021
- Phase: 1/2
- Setting: Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
- Sponsor: Affini-T Therapeutics, Inc.
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT06105021: https://clinicaltrials.gov/study/NCT06105021

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [Affini-T Therapeutics](https://onco.cc/companies/affini-t-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06105021.json